Surfactant Protein A Enhances Alveolar Macrophage Phagocytosis of Apoptotic Neutrophils

Trista L. Schagat, Jessica A. Wofford and Jo Rae Wright

*J Immunol* 2001; 166:2727-2733; doi: 10.4049/jimmunol.166.4.2727

http://www.jimmunol.org/content/166/4/2727

References

This article cites 55 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/166/4/2727.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Surfactant Protein A Enhances Alveolar Macrophage Phagocytosis of Apoptotic Neutrophils

Trista L. Schagat, Jessica A. Wofford, and Jo Rae Wright

Surfactant protein A (SP-A) is an innate immune molecule that binds foreign organisms that invade the lungs and targets them for phagocytic clearance by the resident pulmonary phagocyte, the alveolar macrophage (AM). We hypothesized that SP-A binds to and enhances macrophage uptake of other nonself particles, specifically apoptotic polymorphonuclear neutrophils (PMNs). PMNs are recruited into the lungs during inflammation, but as inflammation is resolved, PMNs undergo apoptosis and are phagocytosed by AMs. We determined that SP-A increases AM phagocytosis of apoptotic PMNs 280 ± 62% above the no protein control value. The increase is dose dependent, and heat-treated SP-A still enhanced uptake, whereas deglycosylated SP-A did not. SP-A enhances phagocytosis via an opsonization-dependent mechanism and binds apoptotic PMNs ~4-fold more than viable PMNs. Also, binding of SP-A to apoptotic PMNs does not appear to involve SP-A’s lectin domain. These data suggest that the pulmonary collectins SP-A and SP-D facilitate the resolution of inflammation by accelerating apoptotic PMN clearance.

The Journal of Immunology, 2001, 166: 2727–2733.

During the resolution of inflammation, polymorphonuclear neutrophils (PMNs) undergo programmed cell death, or apoptosis. This results in plasma membrane changes that cause them to be recognized as nonself and subsequently phagocytosed by macrophages (1, 2). These changes include exposure of phosphatidylserine on the outer leaflet of the plasma membrane (3, 4), loss of sialic acid residues on surface Ags (5), and decreased expression of the glycosylphosphatidylinositol-linked protein CD16 (6). If macrophage recognition and phagocytosis of the apoptotic cells are not efficient, PMNs can proceed into the later stages of apoptosis in which their plasma membranes break down and intracellular enzymes leak into the surrounding tissue, resulting in tissue damage and prolonged inflammation (7, 8).

Both soluble factors and phagocyte membrane receptors have been identified that recognize apoptotic cells and mediate their clearance (reviewed in Ref. 9). Soluble mediators that have been identified include β2-glycoprotein (10) and complement proteins, which becomes deposited on the apoptotic cell surface (11). Also, thrombospondin acts in concert with the phagocyte receptors αβ1 and CD36 to bridge the apoptotic cell with the phagocyte (12). In addition to αβ1 and CD36, other phagocyte receptors that have been identified are the LPS receptor CD14, class A and class B scavenger receptors, and an ATP-binding cassette transporter, ABC-1. Inhibition studies suggest that an unidentified phosphatidylserine receptor and lectin(s) are also involved. As discussed in the review by Savill (13), multiple interactions exist between the apoptotic cell and its phagocyte.

Immunoregulatory proteins have been identified in the lungs. Among these proteins are surfactant proteins A and D (SP-A and SP-D), which are in the collectin protein family of innate immune molecules. Collectins are oligomeric proteins characterized by N-terminal collagen-like domains and C-terminal lectin or carbohydrate binding domains (14, 15). All family members are pattern recognition molecules that bind nonself moieties, thereby targeting the foreign material for rapid clearance by immune cells. SP-A in particular can bind to a variety of substrates, including carbohydrates (16), surfactant lipids and lipid vesicles (17, 18), and proteins (i.e., myosin (19)). Binding of SP-A to both bacteria and lipid vesicles enhances their phagocytosis by macrophages (20–24). The macrophages with which SP-A and SP-D interact are the resident immune cells in the lungs, the alveolar macrophages (AM).

Several in vivo models of pulmonary injury demonstrate the importance of AM phagocytosis of apoptotic PMNs in the resolution of inflammation (25, 26), and it has been suggested that chronic pulmonary inflammation may be a result of inefficient clearance of apoptotic PMNs (27). We hypothesize that when PMNs undergo apoptosis, the changes that occur at the PMN plasma membrane allow SP-A and SP-D to recognize them as nonself. The proteins would then bind the apoptotic PMNs and target them for rapid phagocytosis by AMs. In this way, SP-A and SP-D would protect the pulmonary tissue by quickly resolving inflammation.

To test this hypothesis, we used a well-established assay for detecting macrophage phagocytosis of apoptotic PMNs (2) and showed that SP-A and, to a lesser extent, SP-D accelerate AM phagocytosis of apoptotic PMNs. We then designed a more sensitive flow cytometric assay and showed that SP-A’s effect was time, dose, and opsonization dependent. The effect was not, however, affected by heat treatment of SP-A, but it was partially dependent on SP-A’s N-linked carbohydrates. Furthermore, SP-A binds apoptotic PMNs significantly more than viable PMNs, and

Received for publication May 3, 2000. Accepted for publication November 27, 2000.

Department of Cell Biology, Duke University Medical Center, Durham, NC 27710
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grant HL51134 from the National Heart, Lung, and Blood Institute, National Institutes of Health.
2 Address correspondence and reprint requests to Dr. Jo Rae Wright, Box 3709, Department of Cell Biology, Duke University Medical Center, Durham, NC 27710. E-mail address: j.wright@cellbio.duke.edu
3 Abbreviations used in this paper: PMN, polymorphonuclear neutrophil; SP-A, surfactant protein A; SP-D, surfactant protein D; AM, alveolar macrophage; Ctlq, complement protein 1q; MBL, mannose-binding lectin; CM-DiI, chloromethylbenzamido derivative of 1,1’-dioctadecyl3,3,3’3’-tetramethylindocarbocyanine perchlorate; CTB, CellTracker Blue; MPO, myeloperoxidase.
this binding does not appear to involve SP-A’s carbohydrate recognition domain. Neither the structurally homologous serum lectin mannose-binding lectin (MBL) nor complement protein 1q (C1q) stimulated PMN uptake. Also, SP-A’s effect was specific to AMs, as peritoneal macrophages did not show enhanced phagocytosis of apoptotic PMNs in the presence of SP-A.

Materials and Methods

Materials

All chemicals used were from Sigma (St. Louis, MO) unless otherwise indicated. PBS, RPMI 1640, DMEM, and IMDM were obtained from Life Technologies (Grand Island, NY). Jurkat cells were obtained from American Type Culture Collection (Manassas, VA). The fluorescent labels FITC, Alexa Fluor 488, chloromethylbenzamido derivative of 1,3-diacycl-3,3',3'- tetramethylindocarbocyanine perchlorate (CM-DiI), and CellTracker Blue (CTB) were obtained from Molecular Probes (Eugene OR). Apoptosis detection reagents (PE-labeled annexin and 7-aminactinomycin D) and anti-CD95 Ab were purchased from PharMingen (San Diego, CA).

Animals

Male Sprague Dawley rats were obtained from Charles River (Raleigh, NC) or Taconic Farms (Germantown, NY). Rats weighed 200–400 g.

Protein purification

SP-A was purified from the bronchoalveolar lavage fluid of patients with alveolar proteinosis as previously described (28). Briefly, SP-A was extracted from lavage fluid with butanol and sequential solubilization in octylglucoside and 5 mM Tris, pH 7.4. The SP-A was treated with polymyxin B and resuspended in the appropriate buffer. All SP-A preparations contained 0.02% aztreonam, 0.05% gentamicin, and 10 mM EDTA with 10% FBS. SP-A preparations were 98% pure as determined by hematoxylin differential stain.

Modification of SP-A

Modification of SP-A was carried out using 5 mM Tris, pH 7.4. A solution of 10 mM EDTA was added to the SP-A to neutralize the acidity. SP-A was then dialyzed against 5 mM HEPES, pH 7.0, then labeled with FITC for 1 h. Excess FITC label was removed by dialysis against 5 mM HEPES, pH 7.0.

Cell isolation

AMs were obtained by lung lavage of rats killed by sodium pentobarbital injection. Lungs were lavaged five to seven times with 10 ml of PBS and 0.2 mM EGTA. Cells were collected by centrifugation for 10 min at 330 g and resuspended in the appropriate buffer.

Myeloperoxidase-based phagocytosis assay

Uptake was evaluated based on methods previously described (1, 38, 39). Freshly isolated AMs were suspended at 1 × 106 cells/ml diluent A, then treated with an equal volume of 4% annexin staining. Jurkat cells were 38% annexin positive after Ab treatment.

Fluorescent labeling

Apoptotic PMNs were labeled with either CM-DiI for confocal microscopy or with CTB for flow cytometry. CM-DiI labeling was performed according to the manufacturer’s guidelines with slight modifications; PMNs were suspended at 2 × 106 cells/ml PBS, then treated with 0.75 μM of CM-DiI/106 cells for 10 min at 37°C followed by 15 min on ice. Cells were then washed and suspended at 2.5 × 105 cells/ml IMDM and 0.1% BSA. Macrophages labeled with CM-DiI were obtained by incubating PMNs in IMDM, 0.1% BSA, and 0.1% CTB for 40 min at 37°C in 5% CO2 followed by a second incubation for 30 min in fresh medium without CTB. Labeled PMNs were then suspended at 2.5 × 106 cells/ml IMDM in 0.1% BSA.

Myeloperoxidase-based phagocytosis assay

Uptake was evaluated based on methods previously described (1, 38, 39). Freshly isolated AMs were suspended at 1 × 106 cells/ml IMDM and 10% rat serum and adhered to 48-well tissue culture plates for 1 h at 37°C in 5% CO2. Wells were then washed twice with IMDM, and cultured PMNs were added to each well at a total of 106 cells/ml IMDM with additional medium where indicated. Incubations were performed at 37°C in 5% CO2 for 30 min unless otherwise indicated. Wells were then washed three times with ice-cold PBS, fixed with 2% glutaraldehyde in PBS, and stained for myeloperoxidase (MPO) activity. To stain for MPO activity, the following was added to each well: 0.25 μl of HBSS, 0.1% PBS, 0.25 μl of 0.1 M sodium acetate buffer (pH 6.2), 10 μl of H2O2, and 10 μl of 1.25 mg/ml o-dianisidine. The reaction was conducted for 15 min at room temperature in the dark, then terminated with addition of 10 μl of 1% sodium azide. Control studies showed that AMs were 100% MPO negative, and PMNs

PMN apoptosis

Freshly isolated PMNs were induced to undergo apoptosis by 24-h culture or by UV radiation (10-min exposure, followed by 3- to 4-h culture) as previously described (35, 36). Apoptotic PMNs were then washed and suspended in the appropriate assay medium. The percent apoptosis was evaluated by PharMingen’s apoptosis detection kit using flow cytometry according to the manufacturer’s specifications. Freshly isolated PMNs were 27 ± 5% annexin positive, 24 h-cultured PMNs were 44 ± 12% annexin positive, and UV-irradiated PMNs were 80 ± 4% annexin positive.

Jurkat cell apoptosis

Apoptosis of Jurkat cells was induced by incubating them with anti-Fas mAb (37). Briefly, cells were cultured in RPMI 1640 and 10% heat-inactivated FCS and treated with 2 μg of anti-CD95 Ab 5 × 106 cells/ml for 24 h. Cells were then washed, and the percent apoptosis was evaluated by annexin staining. Jurkat cells were 38% annexin positive after Ab treatment.
were 100% MPO positive. Using light microscopy, cells were scored for the percentage of AMs that had PMNs associated with them. Sample wells were blinded, and a minimum of five fields of view at $\times 100$ objective and 500 macrophages were scored for each sample.

Flow cytometry phagocytosis assay

PKH2-labeled macrophages were incubated 1/3 with CTB-labeled apoptotic PMNs at a final concentration of 1.25 $\times 10^6$ macrophages/ml IMDM and 0.1% BSA in BSA-precoated tubes in the presence of the indicated proteins. Cells were incubated at 37°C with gentle shaking for 60 min unless otherwise indicated. Cells were then washed with ice-cold PBS and 2 mM EDTA and then incubated in 1% formaldehyde and 0.1% BSA in PBS for flow cytometry. Cells were analyzed for both labels, and PKH2-positive cells that were also positive for CTB were considered to have phagocytosed PMNs. Dual-labeled cells compared with total PKH2-positive cells were expressed as the percentage of macrophages that had phagocytosed PMNs.

SP-A binding assay

Cells were labeled using a slight modification of the protocol described in PharMingen’s Apoptosis Detection Kit. Briefly, cells were washed twice with ice-cold PBS, then suspended at 1 $\times 10^7$ cells/ml binding buffer (10 mM Hepes/NaOH (pH 7.4), 0.14 mM NaCl, and 2.5 mM CaCl$_2$). Aliquots (100 $\mu$l) were used for flow cytometry; cells were incubated with 25 $\mu$g/ml FITC-SP-A or Alexa-SP-A for 15 min on ice, then with 5 $\mu$l/tube PE-annexin for 15 min at room temperature. The binding reaction was stopped by adding 0.4 ml of ice-cold binding buffer/tube. Cells were analyzed by flow cytometry within 1 h or were fixed in 1% formaldehyde and stored at 4°C until analysis.

PMN studies measuring binding of different doses of SP-A and modified SP-A were performed as described, except that before labeling, annexin-positive cells were purified using the MACS apoptotic cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s specifications.

Confocal microscopy

Phagocytosis was conducted as described above, except CM-Dil-labeled PMNs were used. After cells had been fixed, smears were made of 2 $\times 10^7$ cells. Slides were air-dried, then treated with 10 $\mu$l of mounting medium (PBS, 50% glycerol, and 2% 1, 4-diazabicyclo[2.2.2]octane), covered with a coverslip, and sealed with nail polish. Cells were then examined under oil (PBS, 50% glycerol, and 2% 1, 4-diazabicyclo[2.2.2]octane), covered with a coverslip, and sealed with nail polish. Confocal microscopy showed that SP-A enhanced AM phagocytosis of apoptotic PMNs.

Results

SP-A increases AM phagocytosis of apoptotic PMNs

We examined the ability of SP-A to enhance AM phagocytosis of apoptotic PMNs using a well-established visual assay that detects phagocytosed PMNs by staining for MPO activity (2). At concentrations that stimulated phagocytosis of bacteria (21, 40), SP-A and, to a lesser extent, SP-D increased AM phagocytosis of apoptotic PMNs (280 ± 62 and 158 ± 16% of control value, respectively; Fig. 1).

The visual assay used in these experiments only allows detection of relatively intact PMNs in AMs. Macrophages break down apoptotic PMNs very rapidly, which results in loss of concentrated MPO activity and an inability to accurately quantitate phagocytosis. Although the percent increase in phagocytosis induced by SP-A was high, the actual percent phagocytosis measured was low (≤6% of AMs contained detectable MPO), and a time course was impossible to detect using the visual assay. We suspected that AMs were rapidly degrading PMNs, and we therefore designed a flow cytometric assay that allowed the detection of phagocytosed PMNs even after they were broken down by AMs. PMNs and AMs were labeled with different fluorescent dyes before phagocytosis. AMs were then analyzed for PMN label. Dual-labeled AMs were considered indicative of phagocytosis. These dyes have been designed for in vivo studies, and cell-to-cell transfer is considered negligible during the time course of these assays (41, 42).

Fig. 2 shows confocal microscopic images of the individually labeled cells (A and B) and images of AMs that had phagocytosed PMNs (C–F). The percent AM phagocytosis of PMNs was determined by scoring confocal images to confirm that the flow cytometric assay was an accurate measure of phagocytosis and not just a measure of cell association. The flow cytometric assay, like the MPO-based assay, showed that SP-A enhanced AM phagocytosis of apoptotic PMNs, and this was confirmed by confocal microscopy. However, baseline phagocytosis in these three assays was significantly different, presumably due to the sensitivity of each assay and the standard set for determining phagocytosis (MPO assay, 2.0 ± 0.3% phagocytosis; flow cytometry assay, 6 ± 1%...
phagocytosis; confocal assay, 47 and 23% phagocytosis). Phagocytosis in the presence of 25 μg/ml SP-A for the three assays was 3.7 ± 0.2% (MPO assay), 18 ± 3% (flow cytometry assay), and 61 and 53% (confocal assay).

The effect of SP-A dose on AM phagocytosis was determined (Fig. 3). Fig. 3A shows an example of the flow analysis of PKH2-positive AMs for the CTB-PMN label. Fig. 3B is the dose-response curve of SP-A’s enhancement of phagocytosis. Phagocytosis was increased in a dose-dependent manner, with a plateau in the effect at 10–25 μg/ml.

The time course of stimulation was also determined (Fig. 4). SP-A’s effect peaked at 60 min, then approached control levels.

We also examined the effect of SP-A on the regulation of peritoneal macrophage phagocytosis of apoptotic PMNs. Baseline phagocytosis of peritoneal macrophages was significantly more than phagocytosis by AMs (29 ± 11 and 6 ± 1%, respectively).

SP-A did not, however, enhance peritoneal macrophage phagocytosis above the baseline (28 ± 7% phagocytosis in the presence of 25 μg/ml SP-A).

**SP-A’s effect peaked at 60 min, then approached control levels.**

**FIGURE 4.** Time course for SP-A’s increase in AM phagocytosis of apoptotic PMNs. PMNs were UV irradiated to induce apoptosis (average, 80 ± 4% by annexin staining), then CTB-labeled and coincubated with PKH2-labeled AMs for the indicated times at 37°C. Cells were analyzed by flow cytometry, and data are expressed as the percentage of AMs that were positive for PMN label. Data are the mean ± SEM (n = 5–6). *, p < 0.05 vs none.

**Effect of SP-A homologues on AM phagocytosis of apoptotic PMNs**

We examined the effect of modifying several aspects of SP-A’s structure on its ability to enhance AM phagocytosis of apoptotic PMNs. After boiling the protein for 10 min, there was no change in its ability to enhance phagocytosis (Fig. 5). However, when SP-A was deglycosylated, its ability to enhance phagocytosis was significantly reduced (Fig. 5). Mock-treated SP-A (SP-A exposed to the deglycosylation reaction but with no N-glycosidase F) had an identical effect on phagocytosis as untreated SP-A (data not shown).

**FIGURE 5.** SP-A’s effect on AM phagocytosis of apoptotic PMNs is not inactivated by heat treatment, but is partially dependent on SP-A’s N-linked carbohydrates. PMNs were UV irradiated to induce apoptosis (average, 80 ± 4% by annexin staining), then CTB-labeled and coincubated with PKH2-labeled AMs for 60 min at 37°C in the presence of the indicated concentration of SP-A. AP, heat-treated SP-A (H. T. SP-A), or deglycosylated SP-A (Deglyc. SP-A). Cells were analyzed by flow cytometry, and data are expressed as the percentage of AMs that were positive for PMN label. Data are the mean ± SEM (n = 4–9). *, p < 0.05 vs none; #, p < 0.05 vs SP-A.

**FIGURE 3.** SP-A increases AM phagocytosis of apoptotic PMNs as determined by flow cytometry. PMNs were UV irradiated to induce apoptosis (average, 80 ± 4% by annexin staining), then CTB-labeled and coincubated with PKH2-labeled AMs for 60 min at 37°C in the presence of the indicated concentrations of SP-A. Cells were washed, fixed, and then analyzed by flow cytometry. A. Analysis of PKH2-positive cells for CTB label in the absence and the presence of 25 μg/ml SP-A. B. Dose-response curve for SP-A. Data are expressed as the percentage of AMs that were positive for PMN label. Data are the mean ± SEM (n = 4–9). *, p < 0.05 vs no SP-A.

**FIGURE 6.** Time course for SP-A’s increase in AM phagocytosis of apoptotic PMNs above the control value (Fig. 5). (Fig. 1 and Table I). The serum collectin MBL did not significantly enhance phagocytosis at either 2 or 10 μg/ml (Table I). We also examined the ability of the structurally homologous C1q to enhance phagocytosis, but no effect was seen (Table I).

**SP-A increases apoptotic PMN phagocytosis by AMs via an opsonization-dependent, but not activation ligand-dependent, mechanism**

It has previously been shown that SP-A can stimulate AM phagocytosis of bacteria by both coating the bacteria, thereby targeting them for phagocytosis (opsonization-dependent phagocytosis) (22, 23, 43), and directly stimulating AMs, thereby causing them to be more phagocytically competent (activation ligand-dependent phagocytosis) (21, 44). To determine the mechanism by which SP-A enhances AM phagocytosis of apoptotic PMNs, these two models were examined using an adherent visual assay. The activation ligand-dependent model was tested by coating wells with SP-A before AM adherence. Adhering AMs to SP-A-coated wells was not sufficient to significantly increase AM phagocytosis of apoptotic PMNs above the control value (Fig. 6). However, when
apoptotic PMNs were pretreated with SP-A for 15 min, and unbound SP-A was removed by washing the PMNs, AMs phagocytosed opsonized PMNs to the same extent as when SP-A was added directly to the assay (Fig. 6).

**SP-A binds apoptotic PMNs**

Macrophage phagocytosis of PMNs coincides with PMN apoptosis (2, 39). Because SP-A seems to stimulate phagocytosis via an opsonization-dependent mechanism (Fig. 6), and stimulation increases as PMN apoptosis increases (data not shown), we hypothesized that SP-A binding to PMNs increases as PMNs undergo apoptosis. To test this, we compared SP-A binding to apoptotic vs viable PMNs. PMNs made apoptotic by culturing were dual-labeled with FITC-SP-A and PE-annexin and analyzed by flow cytometry. The intensity of SP-A binding to annexin-positive (apoptotic) vs annexin-negative (viable) PMNs was compared. Fig. 7 is a representative dot plot of these experiments. SP-A bound to annexin-positive PMNs 4 ± 1-fold more than to annexin-negative PMNs (average ± SEM; n = 3). Annexin alone bound 84% of the PMNs (Fig. 7A), and SP-A alone bound 89% (Fig. 7B). Dual labeling of the PMNs showed that annexin bound 69% and SP-A bound 86% of the cells (Fig. 7C). This binding is dependent on SP-A dose, but does not appear to be saturable at concentrations up to 25 μg/ml (Fig. 7D). An increase in SP-A binding to apoptotic vs viable PMNs was also seen with the PMNs made apoptotic by UV irradiation; SP-A bound annexin-positive PMNs ~2-fold more than annexin-negative PMNs. These data support the opsonization-dependent model of SP-A-mediated AM phagocytosis of apoptotic PMNs. Binding of modified SP-A to PMNs and AMs was compared to determine whether the mechanism of binding to the two cells differed (Table II). Neither heat treatment nor deglycosylation of SP-A significantly reduced SP-A binding to apoptotic PMNs. However, both heat treatment and deglycosylation reduced SP-A binding to AMs. The AM binding data are consistent with published results by Oosting et al. (45).

To characterize the SP-A binding site on apoptotic PMNs, we examined the ability of various sugars to affect SP-A binding. Neither mannose nor mannan, which bind SP-A’s lectin domains, affected SP-A binding to the apoptotic PMNs (98 ± 13 and 99 ± 15% of the SP-A control, respectively). Galactose also had no effect (97 ± 9% of the SP-A control). SP-A binding was not calcium dependent (79 ± 9% of the SP-A control), nor was it inhibited by excess unlabeled SP-A (155 ± 25% of the SP-A control).

To determine whether SP-A has the capacity to bind other apoptotic cells, we induced apoptosis in Jurkat cells by cross-linking Fas on the surface of the cells (37) and compared SP-A binding to

![FIGURE 6](Image 2731) SP-A increases AM phagocytosis of apoptotic PMNs via an opsonization-dependent mechanism. PMNs were UV irradiated to induce apoptosis (average, 80 ± 4% by annexin staining), then CTB-labeled and coincubated with PKH2-labeled AMs for 60 min at 37°C in the presence of the indicated proteins. Cells were then washed, fixed, and analyzed by flow cytometry. Values are reported as % no protein control. AM phagocytosis of apoptotic PMNs was 5.8% under control conditions. Mean ± SEM. 

![FIGURE 7](Image 2731) SP-A binds annexin-positive PMNs 4 ± 1-fold more than annexin-negative PMNs. Peripheral PMNs were isolated and made apoptotic by culturing for 24 h in the absence of serum. Apoptotic PMNs were then washed and incubated for 15 min on ice with or without 25 μg/ml FITC-labeled SP-A, followed by an additional 15-min incubation with or without PE-labeled annexin. Cells were then diluted 5-fold in cold binding buffer and analyzed by flow cytometry within 1 h. The histogram is representative of three experiments. A, PMNs labeled with PE-annexin (84% positive); B, PMNs labeled with FITC-SP-A (89% positive); C, PMNs dual-labeled with PE-annexin and FITC-SP-A (69% positive for both labels); D, graph of the mean relative fluorescence units (RFUs) of Alexa-SP-A bound to annexin-positive PMNs in the presence of increasing concentrations of SP-A. Apoptosis of PMNs was, on the average, 80 ± 4% by annexin staining. Data are the mean ± SEM (n = 3).

**Table I. The effect of SP-A homologues on AM phagocytosis of apoptotic PMNs**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>100%</td>
</tr>
<tr>
<td>SP-A 25 μg/ml</td>
<td>213 ± 33%*</td>
</tr>
<tr>
<td>SP-D 0.5 μg/ml</td>
<td>132 ± 16%</td>
</tr>
<tr>
<td>2 μg/ml</td>
<td>125 ± 7%*</td>
</tr>
<tr>
<td>MBL 2 μg/ml</td>
<td>119 ± 12%</td>
</tr>
<tr>
<td>10 μg/ml</td>
<td>118 ± 13%</td>
</tr>
<tr>
<td>Clq 25 μg/ml</td>
<td>110 ± 19%</td>
</tr>
</tbody>
</table>

* PMNs were UV irradiated to induce apoptosis (average 80 ± 4% by annexin staining); then CTB-labeled and coincubated with PKH2-labeled AMs for 60 min at 37°C in the presence of the indicated proteins. Cells were then washed, fixed, and analyzed by flow cytometry. Values are reported as % no protein control. AM phagocytosis of apoptotic PMNs was 5.8% under control conditions. Mean ± SEM. n = 3–7. *p < 0.05 vs none.

**Table II. SP-A binding to AMs vs apoptotic PMNs: the effect of SP-A modification**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean Fluorescence (RFUs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AMs</td>
</tr>
<tr>
<td>SP-A</td>
<td>58 ± 3</td>
</tr>
<tr>
<td>Heat-treated SP-A</td>
<td>21 ± 2*</td>
</tr>
<tr>
<td>Deglycosylated SP-A</td>
<td>34 ± 1*</td>
</tr>
</tbody>
</table>

* AMs were isolated from bronchoalveolar lavage of normal rats. Apoptotic PMNs were isolated from UV-irradiated rat peripheral PMNs by annexin-coupled magnetic beads. Cells were incubated with 10 μg/ml of the indicated Alexa Fluor 488-labeled proteins for 15 min on ice followed by 15 min at room temperature, then fixed and analyzed by flow cytometry. RFUs, Relative fluorescence units. Mean ± SEM. n = 3. *p < 0.05 vs SP-A.
the apoptotic vs the viable cells. Apoptosis was detectable in 38% of the cells 25 h after induction, and SP-A bound apoptotic Jurkat cells 3-fold more than viable cells.

Discussion

This study demonstrates that the pulmonary collectin, SP-A, can accelerate macrophage phagocytosis of apoptotic PMNs. This occurs via an opsonization-dependent mechanism, and the effect is partially mediated by the N-linked carbohydrates on SP-A. The other pulmonary collectin, SP-D, also enhances phagocytosis of PMNs, although to a lesser extent than SP-A. The serum collectin, MBL, did not significantly enhance phagocytosis. Because PMN apoptosis and subsequent phagocytosis by AMs are necessary for inflammation to be resolved (25–27), our data suggest that the pulmonary collectins may protect pulmonary tissue by facilitating the resolution of inflammation.

Collectins all bind to nonself molecular patterns. Before the current study the reported consequence of this binding was enhanced uptake of bacteria and viruses by phagocytes. The current study suggests that SP-A and SP-D can recognize apoptotic PMNs and enhance their phagocytosis by AMs. This effect was not shared by the serum collectin, MBL, or the structurally homologous complement component, C1q. Previous studies had demonstrated that C1q bound to apoptotic cells, but only in the presence of serum (46). As our experiments were performed without serum, it is not surprising that C1q was unable to enhance phagocytosis. It is possible that MBL may also require serum or other cofactors to enhance phagocytosis of apoptotic cells.

The ability of SP-A to enhance macrophage phagocytosis of apoptotic PMNs was not common to all phagocytes, as peritoneal macrophages did not show increased phagocytosis of apoptotic PMNs in the presence of SP-A. The peritoneal macrophages are, however, primed, because they have migrated into the peritoneum in response to an inflammatory stimulus. This priming may affect the macrophages’ ability to respond to SP-A, and it remains to be determined how the activation state of AMs may affect SP-A’s regulation of their phagocytosis of apoptotic PMNs.

SP-A enhanced AM phagocytosis in a time-dependent manner, with a peak in enhancement observed at 60 min. It was interesting that SP-A’s effect seemed to decrease after 60 min, although this is not statistically significant. This may be due to a decrease in the effective concentration of SP-A in the medium over the course of the assay, perhaps by AM uptake and degradation (47). Alternatively, an apparent reduction in phagocytosis may be due to a breakdown or dissipation of the PMN label after phagocytosis by the AMs, because fluorescence of the PMN label is dependent on its local concentration.

Multiple changes occur on the surface of apoptotic cells, revealing cryptic patterns that SP-A may then recognize as nonself. For example, changes in carbohydrates occur on the plasma membranes of apoptotic cells (5). Although the details of these changes remain to be determined, they appear to involve, at least partially, the loss of sialic acid residues on surface structures. Because mono- and disaccharides have been shown to inhibit phagocytosis of apoptotic cells (48–50), it has been speculated that a lectin receptor is involved in phagocytosis, and several lectin receptors on nonprofessional phagocytes have been identified (48, 50, 51).

It does not appear, however, that SP-A is interacting with the apoptotic PMNs via its lectin domain. Mannan and mannoside, which bind to SP-A’s lectin domain, did not inhibit SP-A binding to the apoptotic PMNs. Also, the tertiary structure of this domain is what imparts the protein’s lectin ability; heat treatment of SP-A eliminates binding to immobilized β-mannose (16), attenuates enhancement of AM phagocytosis of bacteria (21), and reduces SP-A binding to AMs, which is consistent with our data (45). Interestingly, SP-A’s ability to mediate AM phagocytosis of apoptotic PMNs is not eliminated by heat treatment. This observation suggests that some domain other than the lectin domain is responsible for the interaction of the protein with apoptotic PMNs.

Although heat treatment of SP-A did not reduce phagocytosis or SP-A binding to apoptotic PMNs, it did significantly reduce SP-A binding to AMs. Studies attempting to characterize the SP-A receptor on AMs (reviewed by Tino and Wright (52)) suggest that SP-A has multiple interactions with AMs. Our data suggest that heat treatment of SP-A inhibits some of these interactions, but not those interactions required for mediation of AM phagocytosis of apoptotic PMNs.

An SP-A-mediated function that is not dependent on the higher structure of the protein is its ability to interact with lipid vesicles (17, 18). SP-A binds to a variety of lipids, including dipalmitoylphosphatidylcholine. Heat treatment of SP-A does not inhibit its ability to bind lipids, but it does decrease its ability to aggregate them. The only lipid change on the surface of apoptotic cells that has been identified is exposure of phosphatidylserine (3, 4). This phospholipid is actively partitioned to the inner leaflet of the plasma membrane in viable cells, but when cells become apoptotic, this asymmetry is lost, and phosphatidylserine is exposed on the surface of the cell. It seems unlikely that SP-A is binding to phosphatidylserine on apoptotic cells, because it has been previously shown that SP-A does not bind phosphatidylserine (18). It is possible that other unidentified changes in the phospholipid composition of the outer plasma membrane are responsible for SP-A binding to that SP-A may bind phosphatidylserine in the context of the plasma membrane.

Each monomer of SP-A is post-translationally modified by N-linked glycosylations. These glycosylations are not required for SP-A’s lectin activity or for binding to phospholipids (53), but they are involved in viral recognition (31, 54) and aggregation of phospholipid vesicles (17). Interestingly, SP-A’s N-linked carbohydrates are involved in AM phagocytosis of Mycobacterium tuberculosis (20). Also, we and others (45) have found that deglycosylation of SP-A significantly decreases SP-A binding to macrophages. The reduced ability of deglycosylated SP-A to enhance AM phagocytosis of apoptotic PMNs appears to be due to its reduced ability to bind AMs and not to a disrupted interaction with the PMNs.

SP-A not only bound apoptotic PMNs significantly more than viable PMNs, but it also bound apoptotic Jurkat cells significantly more than viable Jurkat cells. This suggests that SP-A is recognizing a motif on the apoptotic PMNs that is common to apoptotic cells regardless of cell type or mode by which apoptosis is induced. Identification of this binding site will not only contribute to a better understanding of how SP-A may regulate apoptotic cell clearance, but will contribute to our understanding of the changes that occur at the cell’s plasma membrane during apoptosis.

SP-A is not the first example of an innate immune molecule that plays a role in clearance of apoptotic cells. Both CD14, the primary LPS receptor, as well as complement have been found to mediate phagocytosis of apoptotic cells (11, 55). It seems possible that the clearance of bacteria and the clearance of apoptotic cells have evolved to encompass similar mechanisms. The goal of both systems is the same: to rid the body of unwanted cells or particles. Understanding how these proteins function will lead to a better understanding of how inflammation may be modulated to minimize potentially harmful proinflammatory responses while maximizing the host response against infection.
Acknowledgments

We are grateful to Dr. J. Michael Cook and the staff of the Duke University Flow Cytometry Facility for their excellent technical assistance and help with experimental design and interpretation. We are also thankful to Dr. Rick Fehon’s laboratory for training and use of the confocal facility.

References


